Page last updated: 2024-09-04

cyc 202 and su 5402

cyc 202 has been researched along with su 5402 in 1 studies

Compound Research Comparison

Studies
(cyc 202)
Trials
(cyc 202)
Recent Studies (post-2010)
(cyc 202)
Studies
(su 5402)
Trials
(su 5402)
Recent Studies (post-2010) (su 5402)
9797393191077

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)su 5402 (IC50)
Epidermal growth factor receptorHomo sapiens (human)0.1867
Platelet-derived growth factor receptor betaHomo sapiens (human)0.2675
Fibroblast growth factor receptor 1Homo sapiens (human)2.0262
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.1867
Fibroblast growth factor receptor 1Mus musculus (house mouse)10
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.1136
Vascular endothelial growth factor receptor 1Mus musculus (house mouse)0.4
Mu-type opioid receptorCavia porcellus (domestic guinea pig)0.02

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Elbaum, D; Lydon, NB; Toledo, LM1

Reviews

1 review(s) available for cyc 202 and su 5402

ArticleYear
The structure-based design of ATP-site directed protein kinase inhibitors.
    Current medicinal chemistry, 1999, Volume: 6, Issue:9

    Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; Anthraquinones; Binding Sites; Catalytic Domain; Cyclin-Dependent Kinases; Drug Design; Enzyme Inhibitors; Humans; Kinetin; Piperazines; Protein-Tyrosine Kinases; Purines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Growth Factor; Roscovitine; Staurosporine; Structure-Activity Relationship

1999